Print pageEmail pageRSS Feeds

We are building a strong, well-run business, structured to deliver sustainable results over the long term.

Along with biotechnology leadership, the ARIAD team is focused on its commitment to deliver long-term value to investors through solid business execution. That means maintaining disciplined cost control, thoughtful capital deployment and the highest standards of corporate governance.

Recent Press Releases
More >>
10/15/14
ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results
10/10/14
ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency
Investor Downloads

Download Documentation AP26113 Phase 1/2 Update – ESMO 2014
Download Documentation Ponatinib Phase 2 GIST Trial – ESMO 2014
Download Documentation Corporate Presentation
More >>

ARIAD Stock Price: $5.71

Stock Symbol: ARIA

Stock Exchange: NASDAQ

Stock Quote at: 10/23/14

4:00 p.m. ET
(US Dollar)
CHANGE (%) Stock is Up 0.12 (2.15%)
VOL5,174,200
OPEN$5.65
PREV. CLOSE$5.59
DAY HIGH$5.82
DAY LOW$5.55
52 WK. HIGH$9.83
Minimum 20 minute delay
Refresh quote
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue